Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer - Webcast

OVERVIEW

Patients with radioactive iodine-refractory thyroid cancer (RAIR-DTC) have poor prognoses and, until recently, there were no effective targeted systemic therapies available for RAIR-DTC. Targeted therapies sorafenib and lenvatinib have been approved by the FDA for treating RAIR-DTC in the last 5 years. Along with these approved therapies, other targeted therapies, such as cabozantinib and vandetanib, which were approved earlier in the decade by the FDA for treating medullary thyroid cancer, are currently in DTC clinical trials. Systemic treatment that balances toxicity with efficacy remains an unmet need in this patient population, which can include patients with relatively long life-expectancies necessitating treatment regimens with extended durations. Targeted therapies hold great promise, but due to the rarity of advanced thyroid cancer, large-scale international clinical trials are needed to determine the best management strategies. Along with reviewing current and developmental therapies for RAIR-DTC, this program will address strategies to match patients to optimal treatments and review that optimal management of side effects is critical.

AMA PRA CATEGORY 1 CREDIT (CME) INFORMATION

To receive a maximum of 1.00 AMA PRA Category 1 CreditTM, participants must complete the online interactive modules and activity evaluation located at education.endocrine.org. Participants must achieve a minimum score of 70% to claim CME credit. After initially completing the modules, if participants do not achieve a minimum score of 70%, they have the option to change their answers and make additional attempts to achieve a passing score. Learners also have the option to clear all answers and start over.

Target Audience

This continuing medical education activity should be of substantial interest to the community of clinical endocrinologists, oncologists, internists, primary care physicians, endocrine nurses, and other healthcare providers involved in the care of patients with thyroid cancer.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Personalize treatment selection for patients with RAI-refractory DTC based on available data and approved agents
  • Implement strategies to mitigate toxicities associated with RAI-refractory DTC therapies
  • Evaluate data from late-stage clinical trials of emerging therapies for RAI-refractory DTC

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
General Endocrinology
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
03/15/2018
Course expires: 
03/15/2019
Rating: 
0

Maria E. Cabanillas, MD
Associate Professor
The University of Texas MD Anderson Cancer Center
Houston, TX

CONTRIBUTING FACULTY

Steven I. Sherman, MD
Associate Vice Provost, Clinical Research
Naguib Samaan Distinguished Professor in Endocrinology
Chair, Department of Endocrine Neoplasia and Hormonal Disorders
The University of Texas MD Anderson Cancer Center
Houston, TX

Lori J. Wirth, MD
Medical Director, Head and Neck Oncology
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Special Programs Committee.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
 

Steering Committee / Presenting Faculty

The steering committee and presenting faculty reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

Maria E. Cabanillas, MD:  Research Grant Recipient and Primary Investigator: Genetech and Eisai; Advisory Group Member: Loxo Oncology, Blueprint Medicines.

Contributing Faculty

The contributing faculty reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests during the content development process for this activity:

Steven I. Sherman, MD: Consultant: Eisai, Sanofi, Veracyte, Inc., Loxo Oncology, Bristol-Myers Squibb; Scientific Board Member: Novo Nordisk

Lori J. Wirth, MDAdvisory Group Member: Amgen, Blueprint Medicines, Eisai, Loxo Oncology, Merck & Co., Novartis, Ignyta

Non-faculty Content Contributors

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Kristen Ndure, Endocrine Society; Chad Williamson and Megan Boone, Rockpointe Corporation: Nothing to disclose

The following SPC Committee members reported financial relationships:

Giuseppe Barbesino, MD: Spouse, employee of Genzyme

DISCLAIMERS

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

USE OF PROFESSIONAL JUDGMENT:

The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

EDUCATIONAL PARTNER

Rockpointe Oncology.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This program is supported by an educational grant from Bayer U.S. LLC.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has received Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Users must follow the steps below to begin the activity before claiming CME credits:

1.  Be logged into personal Endocrine Society account

  • This can be done through the Log in/Register link at the top right corner of the page.
  • When logged in, you will see your name in the blue ribbon at the top of the page.

2.  click the blue Start button in the Start tab to begin the post-test and evaluation

CME INFORMATION AND METHOD OF PARTICIPATION

To receive a maximum of 1.00 AMA PRA Category 1 CreditTM, participants must complete the online interactive modules and activity evaluation located at education.endocrine.org

This enduring material is presented online and in print format. The estimated time to complete this activity, including review of material, is 1 hour. Participants must achieve a minimum score of 70% to claim CME credit. After initially completing the module(s), if participants do not achieve a minimum score of 70%, they have the option to change their answers and make additional attempts to achieve a passing score. Participants also have the option to clear all answers and start over.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation

Accreditation Period

Course opens: 
03/15/2018
Course expires: 
03/15/2019

Please login or create a complimentary account to claim CME and press the start button to begin.

Required Hardware/software

SYSTEM REQUIREMENTS

To complete this activity, participants must have access to a computer or mobile device with an Internet connection and use a major Web browser, such as Internet Explorer 10+, Firefox 32+, Safari, or Google Chrome 37+. In addition, cookies and Javascript must be enabled in the browser’s options.